RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript Summary
RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript Summary
Gross margin for Q3 2024 was 71.4%, demonstrating an increase from previous years due to a higher sales mix of LAL, reduced costs of sales for LDD and LAL, and steady pricing.The following is a summary of the RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript:
以下是RxSight, Inc.（RXST）2024年第三季度業績會議文本摘要：
Financial Performance:
財務表現：
RxSight reported a Q3 2024 revenue of $35.3 million, up 59% year-over-year.
LAL revenue was $24.2 million, representing 69% of the total revenue.
Gross margin for Q3 2024 was 71.4%, demonstrating an increase from previous years due to a higher sales mix of LAL, reduced costs of sales for LDD and LAL, and steady pricing.
GAAP net loss was $6.3 million, a reduction from a GAAP net loss of $12.4 million in Q3 2023.
RxSight報告2024年第三季度營業收入爲3530萬美元，同比增長59%。
LAL營業收入爲2420萬美元，佔總營業收入的69%。
2024年第三季度的毛利率爲71.4%，這表明由於LAL銷售比例較高，LDD和LAL銷售成本降低，價格穩定等因素，毛利率較往年有所增加。
根據GAAP淨損失爲630萬美元，較2023年第三季度的1240萬美元的GAAP淨損失有所減少。
Business Progress:
業務進展:
RxSight experienced robust growth in its LDD installed base, with a total of 888 units by the end of Q3 2024.
Full rollout of LAL+ in the U.S. and approval in Canada with significant clinical approval demonstrated.
Anticipates further expansion in North American markets and has planned regulatory and commercial expansions into Asia and Europe.
RxSight在其LDD安裝基數方面經歷了強勁增長，截至2024年第三季度末共計888台設備。
美國全面推出了LAL+，並獲得了加拿大的批准，展示了顯著的臨床批准。
預計在北美市場進一步擴張，並計劃在亞洲和歐洲進行監管和商業擴張。
Opportunities:
機會：
The recently approved low-diopter LAL+ powers expected to broaden appeal and usability amongst surgeons, expanding potential customer base.
最近獲得批准的低度數LAL+動力預計將增加外科醫生的吸引力和可用性，擴大潛在客戶群。
Risks:
風險：
Seasonal fluctuations in surgery volumes impacting revenue, as seen with weaker Q3 due to vacations and natural events like hurricanes which may continue to pose risks.
手術量因季節波動而影響營業收入，如第三季度的疲軟受到假期和颶風等自然事件的影響，可能會繼續帶來風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
